MediSieve's device captures Leukaemia blasts from the bloodstream in order to reduce the patient's white blood cell count.

Leukaemia is a cancer of the bone marrow where white blood cells (WBC) are produced. When a person has Leukaemia, the bone marrow produces a lot of abnormal and immature WBCs, or “blasts”, which multiply rapidly and are incapable of contributing to immune function.

These eventually spill over into the bloodstream crowding out normal cells. High levels of circulating Leukaemia blasts present problems for both chemotherapy and newer targeted monoclonal antibody therapies. The circulating cells can prevent the therapeutics from reaching the bone marrow where the disease begins and the death of large numbers of circulating cells can create potentially life-threatening side effects for the patient.

Significant worldwide burden

176k affected annually
1 death every 9 minutes

High morbidity and mortality

Mortality rate 35%

Stroke

Fatigue

Pneumonia

Heavy burden of patient care

Draining Chemotherapies

Constant blood tranfusions

long patient care

The long-term goal for clinical trials is to prove the value of magnetic filtration as a pre-treatment to traditional or next generation Leukaemia therapies. The MediSieve technology would only remove the blasts and would bring a patient's WBC count down to normal levels, reducing the side-effects of a further chemotherapy.

Latest News

A Great Start to 2020

A Great Start to 2020
January 16, 2020

If you missed it, before Christmas, we announced that Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, had been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35

MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35
December 19, 2019

Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.